Reuters -- OSI Pharmaceuticals Inc's (OSIP.O) cancer drug Tarceva extended the survival of patients with advanced non-small cell lung cancer (NSCLC), when used immediately after chemotherapy, according to further results from the late-stage Saturn study.
